Development of a New Fusion-Enhanced Oncolytic Immunotherapy Platform Based on Herpes Simplex Virus Type 1

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-019-0682-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Ribonucleotide Reductase of Herpes Simplex Virus Type 2 Resembles That of Herpes Simplex Virus Type 1.

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
1984English

Herpes Simplex Virus 1 Envelope Cholesterol Facilitates Membrane Fusion

Frontiers in Microbiology
Microbiology
2017English

Development of an Oncolytic Herpes Simplex Virus Using a Tumor-Specific HIF-responsive Promoter

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2010English

Genital Herpes Simplex Virus Type 1 in Women.

Sexually Transmitted Infections
DermatologyInfectious Diseases
1994English

Antiviral Activity of Antilipidemic Compounds on Herpes Simplex Virus Type 1.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1980English

Manipulation of Herpes Simplex Virus Type 1 by Dielectrophoresis

Biochimica et Biophysica Acta - General Subjects
BiochemistryMolecular BiologyBiophysics
1998English

Herpes Simplex Virus Type 1 and Bovine Herpesvirus 1 Latency

Clinical Microbiology Reviews
ImmunologyEnvironmentalPublic HealthMicrobiologyMicrobiology EpidemiologyInfectious DiseasesOccupational Health
2003English

Oligomeric Structure of Glycoproteins in Herpes Simplex Virus Type 1.

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
1996English

Comprehensive Characterization of Extracellular Herpes Simplex Virus Type 1 Virions

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy